Immunome (IMNM) Competitors $9.21 -0.47 (-4.86%) Closing price 04:00 PM EasternExtended Trading$9.32 +0.11 (+1.19%) As of 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMNM vs. AKRO, APLS, ZLAB, CRNX, KYMR, RARE, TLX, NAMS, VKTX, and XENEShould you be buying Immunome stock or one of its competitors? The main competitors of Immunome include Akero Therapeutics (AKRO), Apellis Pharmaceuticals (APLS), Zai Lab (ZLAB), Crinetics Pharmaceuticals (CRNX), Kymera Therapeutics (KYMR), Ultragenyx Pharmaceutical (RARE), Telix Pharmaceuticals (TLX), NewAmsterdam Pharma (NAMS), Viking Therapeutics (VKTX), and Xenon Pharmaceuticals (XENE). These companies are all part of the "pharmaceutical products" industry. Immunome vs. Its Competitors Akero Therapeutics Apellis Pharmaceuticals Zai Lab Crinetics Pharmaceuticals Kymera Therapeutics Ultragenyx Pharmaceutical Telix Pharmaceuticals NewAmsterdam Pharma Viking Therapeutics Xenon Pharmaceuticals Immunome (NASDAQ:IMNM) and Akero Therapeutics (NASDAQ:AKRO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, media sentiment, earnings, risk, dividends, profitability and institutional ownership. Do insiders & institutionals hold more shares of IMNM or AKRO? 44.6% of Immunome shares are owned by institutional investors. 7.7% of Immunome shares are owned by insiders. Comparatively, 7.1% of Akero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has preferable earnings and valuation, IMNM or AKRO? Akero Therapeutics has lower revenue, but higher earnings than Immunome. Akero Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmunome$9.04M88.68-$292.96M-$3.08-2.99Akero TherapeuticsN/AN/A-$252.06M-$2.00-21.73 Does the media prefer IMNM or AKRO? In the previous week, Akero Therapeutics had 13 more articles in the media than Immunome. MarketBeat recorded 25 mentions for Akero Therapeutics and 12 mentions for Immunome. Akero Therapeutics' average media sentiment score of 1.23 beat Immunome's score of 0.94 indicating that Akero Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunome 6 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Akero Therapeutics 12 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, IMNM or AKRO? Immunome has a beta of 1.92, meaning that its share price is 92% more volatile than the S&P 500. Comparatively, Akero Therapeutics has a beta of -0.24, meaning that its share price is 124% less volatile than the S&P 500. Do analysts recommend IMNM or AKRO? Immunome currently has a consensus price target of $22.89, suggesting a potential upside of 148.52%. Akero Therapeutics has a consensus price target of $81.14, suggesting a potential upside of 86.71%. Given Immunome's higher probable upside, analysts plainly believe Immunome is more favorable than Akero Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immunome 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Akero Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is IMNM or AKRO more profitable? Akero Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -1,687.08%. Akero Therapeutics' return on equity of -15.84% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets Immunome-1,687.08% -76.10% -65.14% Akero Therapeutics N/A -15.84%-14.59% SummaryImmunome and Akero Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Get Immunome News Delivered to You Automatically Sign up to receive the latest news and ratings for IMNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMNM vs. The Competition Export to ExcelMetricImmunomeMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$801.64M$3.12B$5.78B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-2.9921.3074.5925.92Price / Sales88.68258.41453.9085.92Price / CashN/A45.3337.0859.91Price / Book4.069.6112.156.29Net Income-$292.96M-$53.29M$3.28B$270.85M7 Day Performance-12.45%0.29%0.98%3.36%1 Month Performance-7.06%8.91%7.20%6.41%1 Year Performance-37.39%13.14%63.06%28.26% Immunome Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMNMImmunome2.1085 of 5 stars$9.21-4.9%$22.89+148.5%-33.1%$801.64M$9.04M-2.9940High Trading VolumeAKROAkero Therapeutics4.0658 of 5 stars$44.57-0.3%$81.14+82.1%+75.4%$3.58BN/A-22.2930Positive NewsInsider TradeAPLSApellis Pharmaceuticals4.3045 of 5 stars$26.91-4.3%$34.12+26.8%-33.8%$3.55B$781.37M-14.79770News CoveragePositive NewsZLABZai Lab3.0223 of 5 stars$31.33+1.9%$56.35+79.9%+50.6%$3.44B$398.99M-15.361,869Insider TradeGap UpHigh Trading VolumeCRNXCrinetics Pharmaceuticals3.6943 of 5 stars$35.14-1.3%$68.86+96.0%-33.5%$3.35B$1.04M-8.55210Positive NewsKYMRKymera Therapeutics2.6662 of 5 stars$43.26-0.6%$58.76+35.8%+3.2%$3.11B$47.07M-12.47170Positive NewsRAREUltragenyx Pharmaceutical4.4719 of 5 stars$31.51-1.0%$81.50+158.6%-44.6%$3.07B$560.23M-5.701,294Positive NewsAnalyst ForecastTLXTelix Pharmaceuticals3.6552 of 5 stars$9.05-0.1%$22.33+146.8%N/A$3.07B$516.72M0.00N/AAnalyst ForecastNAMSNewAmsterdam Pharma3.4813 of 5 stars$25.09-7.1%$41.55+65.6%+64.6%$3.04B$45.56M-15.494News CoveragePositive NewsInsider TradeHigh Trading VolumeVKTXViking Therapeutics4.2831 of 5 stars$25.48-5.6%$86.92+241.1%-57.7%$3.03BN/A-16.6520Positive NewsXENEXenon Pharmaceuticals2.3736 of 5 stars$38.19-2.6%$53.30+39.6%-3.7%$3.02B$9.43M-10.76210Positive News Related Companies and Tools Related Companies AKRO Competitors APLS Competitors ZLAB Competitors CRNX Competitors KYMR Competitors RARE Competitors TLX Competitors NAMS Competitors VKTX Competitors XENE Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMNM) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunome, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunome With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMNM Stock Alerts